溶瘤麻疹病毒、巨噬细胞和癌细胞之间的相互作用诱发了促炎性肿瘤微环境

IF 7.2 2区医学

Oncoimmunology Pub Date : 2024-07-10 DOI:10.1080/2162402x.2024.2377830

Camille Chatelain, Laurine Berland, Marion Grard, Nicolas Jouand, Judith Fresquet, Joëlle Nader, Ugo Hirigoyen, Tacien Petithomme, Chantal Combredet, Elvire Pons-Tostivint, Delphine Fradin, Lucas Treps, Christophe Blanquart, Nicolas Boisgerault, Frédéric Tangy, Jean-François Fonteneau

引用次数: 0

摘要

减毒麻疹病毒（MV）可在缺乏Ⅰ型干扰素（IFN-Ⅰ）产生或反应能力的恶性胸膜间皮瘤（MPM）细胞中发挥其溶瘤活性。然而，恶性胸膜间皮瘤细胞中的其他细胞也能产生IFN-I。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Interplay between oncolytic measles virus, macrophages and cancer cells induces a proinflammatory tumor microenvironment

Attenuated measles virus (MV) exerts its oncolytic activity in malignant pleural mesothelioma (MPM) cells that lack type-I interferon (IFN-I) production or responsiveness. However, other cells in t...

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.